Mobile blood collection sites and their roles in providing safe and adequate supply: A six-year experience

doi:10.1007/s11515-018-1497-z

Front. Biol.

2018, Vol. 13

Issue (3) : 226-234 https://doi.org/10.1007/s11515-018-1497-z

RESEARCH ARTICLE

Mobile blood collection sites and their roles in providing safe and adequate supply: A six-year experience

Mostafa Paridar¹, Abbas Khosravi²(

), Mohammad-Ali Jalali-Far², Sima Zolfaghari², Omid Kiani Ghaleh Sardi³, Mehdi Sajadi⁴

¹. Deputy of Management and Resources Development, Ministry of Health and Medical Education,Tehran, Iran
². Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
³. Department of Hematolog, Iran University of Medical Sciences,Tehran,Iran
⁴. Faculty of Allied Medicine, Birjand University of Medical Sciences, Birjand, Iran

Download: PDF(570 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

BACKGROUND: The determination of the role of mobile sites, as compared with fixed sites, in providing safe blood supply will help with the planning of future programs.

MATERIALS and METHODS: This retrospective study was carried out at the Khuzestan Blood Transfusion Organization from 2007 to 2012. Samples of the blood collected at mobile sites and fixed sites were compared. Comparisons took into consideration noticeable trends as well as the prevalence of major TTIs including HIV, HBV and HCV.

RESULTS: The total number of blood donations from 2007 to 2012 was 621117 out of which 89590 (14.43%) were collected from mobile sites. The overall blood donation index was estimated at 23.8 per 1000 population. The prevalence of HIV, HBV and HCV in mobile site donations was 5.31, 320.34 and 117.4, and in fixed sites was 5.31, 214.72 and 104.83 per 100000 donations respectively. HBV prevalence in mobile sites was significantly higher than in fixed sites (p = 0.014).

CONCLUSION: The blood donation index in Khuzestan province is much better when compared with areas of similar socio-economic status as well as neighboring countries. The allotment of blood units collected by mobile teams is lower than that of national reports. In addition, the prevalence of TTIs in mobile site blood donations was higher than at fixed sites.

Keywords fixed sites mobile sites blood donations TTIs Iran

Corresponding Author(s): Abbas Khosravi

Online First Date: 02 July 2018 Issue Date: 31 July 2018

Cite this article:

Mostafa Paridar,Abbas Khosravi,Mohammad-Ali Jalali-Far, et al. Mobile blood collection sites and their roles in providing safe and adequate supply: A six-year experience[J]. Front. Biol., 2018, 13(3): 226-234.

URL:

https://academic.hep.com.cn/fib/EN/10.1007/s11515-018-1497-z
https://academic.hep.com.cn/fib/EN/Y2018/V13/I3/226

Year	Screening/confirmatory tests
	HBs Ag		Anti-HCV		HIV
	Screening kit (Manufacturer)	HBs Ag confirmatory	Screening kit (Manufacturer)	HCV RIBA	Screening kit (Manufacturer)	Confirmatory (Manufacturer)
2007	Enzygnost HBs Ag 5.0 (Dade-Behring)	HBs Ag confirmatory test(Dade Behring)	HCV 3.0 with enhanced SAVe (ORTHO) Hepanostika HCV Ultra (bioMérieux)	HCV BLOT 3.0 (Genelabs) HCV BLOT 3.0 (MP Diagnostics) Inno-LIA HCV Score (Innogenetics)	Genscreen ULTRA HIV Ag-Ab Vironostika HIV Uni-Form II Ag/AbINNO-LIA HIV I/II Score(Bio-rad/bioMérieux)	INNO-LIA HIV I/II Score HIV BLOT 2.2 (Innogenetics /Genelabs)
2008	Enzygnost HBs Ag 5.0 (Dade-Behring)	HBs Ag confirmatory test (Dade Behring)	HCV 3.0 with enhanced SAVe (ORTHO) Hepanostika HCV Ultra (bioMérieux)	Inno-LIA HCV Score (Innogenetics)	Genscreen ULTRA HIV Ag-Ab Vironostika HIV Uni-Form II Ag/AbINNO-LIA HIV I/II Score(Bio-rad/bioMérieux)	INNO-LIA HIV I/II Score HIV BLOT 2.2 (Innogenetics /Genelabs)
2009	Enzygnost HBs Ag 5.0 (Dade-Behring) Enzygnost HBs Ag 6.0 (Siemens)	HBs Ag confirmatory test(Dade Behring) HBs Ag confirmatory test(Siemens)	HCV 3.0 with enhanced SAVe (ORTHO)	Inno-LIA HCV Score (Innogenetics) HCV BLOT 3.0 (Genelabs)	Genscreen ULTRA HIV Ag-Ab Vironostika HIV Uni-Form II Ag/AbINNO-LIA HIV I/II Score(Bio-rad/bioMérieux)	INNO-LIA HIV I/II Score HIV BLOT 2.2 (Innogenetics /Genelabs)
2010	Enzygnost HBs Ag 6.0 (Siemens)	HBs Ag confirmatory test(Siemens)	HCV 3.0 with enhanced SAVe (ORTHO) Hepanostika HCV Ultra (bioMérieux)	Inno-LIA HCV Score (Innogenetics) HCV BLOT 3.0 (MP Diagnostics)	Genscreen ULTRA HIV Ag-Ab Vironostika HIV Uni-Form II Ag/AbINNO-LIA HIV I/II Score(Bio-rad/bioMérieux)	INNO-LIA HIV I/II Score HIV BLOT 2.2 (Innogenetics /MP Diagnostics)
2011	Enzygnost HBs Ag 6.0 (Siemens)	HBs Ag confirmatory test(Siemens) Anti-HBcAb(Siemens)	Hepanostika HCV Ultra (bioMérieux)	Inno-LIA HCV Score (Innogenetics) HCV BLOT 3.0 (MP Diagnostics)	Genscreen ULTRA HIV Ag-Ab Vironostika HIV Uni-Form II Ag/AbINNO-LIA HIV I/II Score(Bio-rad/bioMérieux)	INNO-LIA HIV I/II Score HIV BLOT 2.2 (Innogenetics /MP Diagnostics)
2012	Enzygnost HBs Ag 6.0 (Siemens)	Anti-HBcAb(Siemens)	Hepanostika HCV Ultra (bioMérieux)	HCV BLOT 3.0 (MP Diagnostics)	Genscreen ULTRA HIV Ag-Ab Vironostika HIV Uni-Form II Ag/AbINNO-LIA HIV I/II Score(Bio-rad/bioMérieux)	INNO-LIA HIV I/II Score HIV BLOT 2.2 (Innogenetics /MP Diagnostics)

Tab.1 The screening/confirmatory test kits (2007-2012)

Fig.1 Number of donations during 2007 to 2012 based on donation status.

Fig.2 Number of donations in fixed and mobile sites during 2007 to 2012.

Fig.3 Trend of TTIs in Fixed sites blood donations.

Fig.4 Trend of TTIs in Mobile sites blood donations.

Tab.2 TTIs prevalence(per 100000) in Mobile sites in compared with Fixed sites

1	Abhishekh B, Usha K (2013). Donor profile and blood safety: comparison between fixed (institute) and mobile site (CAMP) blood collections. International Journal of Current Research and Review, 5(1): 32–35
2	Adouani B, Alami R, Laouina A, Benahadi A, Boulahdid S, Mokhtari A, Soulaymani A, Abouyoub A, Benajiba M (2013). Hepatitis B in Moroccan blood donors: a decade trend of the HBsAg prevalence in a resources limited country. Transfus Med, 23(6): 432–437 https://doi.org/10.1111/tme.12054
3	Al Shaer L, AbdulRahman M, John T J, AlHashimi A (2012). AbdulRahman M, John TJ, AlHashimi A. Trends in prevalence, incidence, and residual risk of major transfusion‐transmissible viral infections in United Arab Emirates blood donors: impact of individual‐donation nucleic acid testing, 2004 through 2009. Transfusion, 52(11): 2300–2309 https://doi.org/10.1111/j.1537-2995.2012.03740.x
4	Belayneh T, Messele G, Abdissa Z, Tegene B (2013). Blood requisition and utilization practice in surgical patients at University of Gondar Hospital, Northwest Ethiopia. Journal of blood transfusion. 2013 758910
5	Carey P M, High P M, Schlumpf K S, Johnson B R, Mast A E, Rios J A, Simon T L, Wilkinson S L (2012). Donation return time at fixed and mobile donation sites. Transfusion, 52(1): 127–133 https://doi.org/10.1111/j.1537-2995.2011.03235.x
6	Cheraghali A (2012). Overview of blood transfusion system of Iran: 2002–2011. Iran J Public Health, 41(8): 89
7	Chiamchanya N (2014). The prevalence of transfusion-transmissible infection in blood donors in Thammasat University Hospital between 2007–2012. Journal of the Medical Association of Thailand= Chotmaihet thangphaet. 97(10): 1055–63
8	Flichman D M, Blejer J L, Livellara B I, Re V E, Bartoli S, Bustos J A, Ansola C P, Hidalgo S, Cerda M E, Levin A E, Huenul A, Riboldi V, Treviño E M C, Salamone H J, Nuñez F A, Fernández R J, Reybaud J F, Campos R H (2014). Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. BMC Infect Dis, 14(1): 218 https://doi.org/10.1186/1471-2334-14-218
9	Gao X, Cui Q, Shi X, Su J, Peng Z, Chen X, Lei N, Ding K, Wang L, Yu R, Wang N (2011). Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis, 11(1): 88 https://doi.org/10.1186/1471-2334-11-88
10	Gharehbaghian A (2012). Introduction of a program for voluntary blood donations in Iran (blood transfusion status in Iran). ISBT Sci Ser, 7(1): 183–187 https://doi.org/10.1111/j.1751-2824.2012.01541.x
11	Hong Y, Huang X, Ling H, Liao H (2012). Prevalence and trend of HIV infection among voluntary blood donors in China since implementation of the Blood Donation Law: a systematic review and meta‐analysis. Trop Med Int Health, 17(8): 978–988 https://doi.org/10.1111/j.1365-3156.2012.03019.x
12	Iran Ministry of health (2011). Center for disease control. Annual report of HIV in Iran. December of 2011
13	James A B, Josephson C D, Shaz B H, Schreiber G B, Hillyer C D, Roback J D (2014). The value of area‐based analyses of donation patterns for recruitment strategies. Transfusion, 54(12): 3051–3060 https://doi.org/10.1111/trf.12740
14	Kasraian L (2010). Trends in the frequency of blood donors donating blood to be tested for HIV in Shiraz from 2004 to 2006. Transfus Med, 20(2): 127 https://doi.org/10.1111/j.1365-3148.2009.00975.x
15	Keshvari M, Sharafi H, Alavian S M, Mehrabadi H, Zolfaghari S (2015). Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. Transfus Apheresis Sci, 53(1): 38–47 https://doi.org/10.1016/j.transci.2015.03.003
16	Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: A systematic review and meta-analysis. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2013;18(8): 674
17	Likatavicius G, Hamers F F, Downs A M, Alix J, Nardone A (2007). Trends in HIV prevalence in blood donations in Europe, 1990–2004. AIDS, 21(8): 1011–1018 https://doi.org/10.1097/QAD.0b013e3280b07dd7
18	Lucky T T, Seed C R, Keller A, Lee J, McDonald A, Ismay S, Wand H, Wilson D P (2013). Trends in transfusion‐transmissible infections among Australian blood donors from 2005 to 2010. Transfusion, 53(11): 2751–2762 https://doi.org/10.1111/trf.12144
19	Maghsudlu M, Nasizadeh S (2011). Iranian blood donors’ motivations and their influencing factors. Transfus Med, 21(4): 247–252 https://doi.org/10.1111/j.1365-3148.2011.01077.x
20	Maghsudlu M, Nasizadeh S, Abolghasemi H, Ahmadyar S (2009). Blood donation and donor recruitment in Iran from 1998 through 2007: ten years’ experience. Transfusion, 49(11): 2346–2351 https://doi.org/10.1111/j.1537-2995.2009.02309.x
21	Meena M, Jindal T, Hazarika A (2011). Prevalence of hepatitis B virus and hepatitis C virus among blood donors at a tertiary care hospital in India: a five‐year study. Transfusion, 51(1): 198–202 https://doi.org/10.1111/j.1537-2995.2010.02801.x
22	Mirrezaie S M, Saber H R, Hajibeigi B, Salekmoghaddam E, Abbasian A, Alavian S M (2014). Impact of HBV vaccination on prevalence of hepatitis B virus infection among volunteer blood donors in Tehran-Iran. Shiraz E Med J, 15(2): e18066 https://doi.org/10.17795/semj18066
23	Mohammadali F, Pourfathollah A A (2014). Changes in Frequency of HBV, HCV, HIV and Syphilis Infections among Blood Donors in Tehran Province 2005–2011. Arch Iran Med, 17(9): 613
24	Pourfathollah A, Hosseini Divkolaye N, Seighali F (2015). Four decades of National Blood Service in Iran: outreach, prospect and challenges. Transfus Med, 25(3): 138–143 https://doi.org/10.1111/tme.12214
25	Razjou F, Maghsudlu M, Nasizadeh S, Zadsar M (2012). The impact of donor selection on blood safety in Iran. Transfus Apheresis Sci, 47(1): 13–16 https://doi.org/10.1016/j.transci.2012.03.001
26	Rose W N, Dayton P J, Raife T J (2011). An analysis of mobile whole blood collection labor efficiency. Transfusion, 51(7pt2): 1609– 1612 https://doi.org/10.1111/j.1537-2995.2011.03221.x
27	Rudowska E, Basta L, Piwowarska G, Drybańska B, Dylag S (2011). [The epidemiological trends connected with detection of HIV, HCV, HBV and syphilis markers in blood donors in the years 2006–2009]. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego. 30(177): 181–6
28	Shi L, Wang J, Liu Z, Stevens L, Sadler A, Ness P, Shan H (2014). Blood donor management in China. Transfus Med Hemother, 41(4): 273–282 https://doi.org/10.1159/000365425
29	Singh K, Bhat S, Shastry S (2009). Trend in seroprevalence of Hepatitis B virus infection among blood donors of coastal Karnataka, India. J Infect Dev Ctries, 3(05): 376–379
30	Song Y, Bian Y, Petzold M, Ung C O L (2014). Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One, 9(4): e94528 https://doi.org/10.1371/journal.pone.0094528
31	Suligoi B, Raimondo M, Regine V, Salfa M C, Camoni L (2010). Epidemiology of human immunodeficiency virus infection in blood donations in Europe and Italy. Blood Transfus, 8(3): 178
32	Uzun B, Güngör S, Demirci M (2013). Seroprevalence of transfusion transmissible infections among blood donors in western part of Turkey: A six-year study. Transfus Apheresis Sci, 49(3): 511–515 https://doi.org/10.1016/j.transci.2013.02.039
33	Van Veen T, Hunt J A (2015). Tissue engineering red blood cells: a therapeutic. J Tissue Eng Regen Med, 9(7): 760–770 https://doi.org/10.1002/term.1885

[1]	Seyed Mehdi Sajjadi,Abbas Khosravi,Jalil Pakravesh,Zahra-soheila Soheili,Shahram Samiei,Saeed Mohammadi,Mohammad Ali Jalali far. Factor XIII Val34Leu polymorphism and risk of recurrent pregnancy loss in Iranian population: a case control study[J]. Front. Biol., 2016, 11(6): 471-475.
[2]	Elham DAVOUDI-DEHAGHANI, Ali Mohammad FOROUGHMAND, Babak SAFFARI, Massoud HOUSHMAND, Hamid GALEHDARI, Mehdi SHAFA SHARIAT PANAHI, Majid YAVARIAN, Mohammad Hossein SANATI, Somayeh TORFI. Mitochondrial DNA sequence diversity in three ethnic populations from the South-west Iran: a preliminary study[J]. Front Biol, 2011, 6(5): 422-432.

Viewed

Full text

Abstract

Cited

Shared

Discussed